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 Hepatitis C virus (HCV) is the most common blood-borne pathogen in the United 
States.  The “Baby Boomer” population, adults born between the years 1945 and 1965, is 
considered a high-risk population as 75% of adults with HCV were born within this 
timeframe.  The U. S. Preventive Services Task Force (USPSTF) made it a Grade B 
recommendation in 2013 for all adults born in this birth cohort to be screened for HCV 
even if asymptomatic.  Hepatitis C virus is associated with many negative sequela 
including liver fibrosis, cirrhosis, hepatocellular carcinoma, and death.  With successful 
treatment regimens available that yield a 90-100% cure rate, it is prudent and 
recommended to screen this birth cohort.   
 Eagle Ridge Medical located in Brighton, Colorado and its sister clinic located in 
Fort Lupton, Colorado do not currently have a standardized approach for HCV screening 
of this population.  The researcher of this project has therefore implemented an approach 
for screening that includes an electronic health record (EHR) initiation of a screening 
alert (reminder) for the four physicians at these clinics.  She also mailed an informative 
letter to this population that included information about the national recommendation and 
screening of this birth cohort in an attempt to increase screening rates at these 
organizations.  This birth cohort includes adults born between the years 1945 and 1965. 
iv 
 
The researcher performed a chart audit of 5% of this population that included 1,906 
patients in this birth cohort (N = 95) both before and after implementation of this project 
to compare screening rates.  The researcher also performed a chart audit on patients who 
were seen in both of these clinics six weeks prior and six weeks after project 
implementation; 466 patients were seen in the six weeks prior to implementation and 
three of them had been screened for HCV (0.6%) and 421 patients were seen in the six 
weeks after the project implementation and 57 of them had been screened for HCV 
(13.5%).  The researcher anticipated screening rates would increase after this project had 
been implemented--they did as they rose by 4.1% using the 5% systematic sampling 
method and 12.9% during the six-week study period in which one positive result was 
noted.  Many of the individuals born within this population have many years left to live if 
successfully treated and ultimately deserve the opportunity to be screened for HCV and 
treated accordingly.  The effects of this study are expected to have a positive impact for 
the future of this birth cohort.  Identifying patients who are positive for HCV will allow 
them the opportunity for treatment and a high potential of HCV eradication as there is a 
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 Hepatitis C virus (HCV) is a blood-borne disease and a global problem that 
impacts multiple individuals.  Hepatitis C virus was first recognized in 1974 but it was 
not until 1989 that it was classified by molecular means.  Hepatitis C virus is a “positive-
strand RNA virus that belongs to the family Flaviviridae” (Kesli, Polat, Terzi, Kurtoglu, 
& Uyar, 2011, p. 4089).  Hepatitis C is either acute--with an incubation phase of about 6 
to 10 weeks--or chronic in nature.  In the acute phase, the individual is generally 
asymptomatic and rarely encounters grave diseases.  Approximately 15-25% of infected 
individuals naturally clear Hepatitis C virus within six months of exposure without any 
medical management or intervention.  Reasons for this spontaneous clearance of the virus 
are not known.  The remaining 75-85% of individuals will go on to develop chronic 
Hepatitis C infection (Centers for Disease Control and Prevention [CDC], 2016).  
Chronic Hepatitis C is diagnosed when a patient is positive for the virus for longer than 
six months.  Chronic hepatitis C causes multiple serious sequela, some can be fatal: liver 
fibrosis or cirrhosis, liver failure, and hepatocellular carcinoma.  Hepatitis C virus is the 
“leading cause of death from liver disease and the most common reason for liver 
transplantation in the United States” (Fathauer & Meek, 2012, p. 338).  
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 Multiple factors are involved with the risk of contracting HCV.  Individuals who 
partake in high-risk activities such as injection drug use (either current or former and 
those who injected only one time if it was done many years ago) are at high risk of 
contracting HCV.  Other individuals at risk include recipients of clotting factor 
concentrates made before 1987 when more progressive safe approaches of manufacturing 
of these concentrates were established.  Recipients of solid organ transplants or blood 
transfusions before 1992, when universal screening measures were introduced, are also 
considered at high-risk.  Individuals who undergo or underwent chronic hemodialysis or 
those with identified contact with HCV such as healthcare workers receiving a needle 
stick injury of someone who is positive for HCV or recipients of organs or blood from a 
donor who tested positive for HCV are also at high-risk.  Other high-risk individuals 
include those who are human immunodeficiency virus (HIV)-positive and children born 
to mothers who are HCV-positive.  
Another high-risk population is the “Baby Boomer” generation or persons born 
between the years 1945 and 1965.  It is estimated that 75% of adults with Hepatitis C 
virus were born between 1945 and 1965.  With this alarming percentage, it is not 
surprising a current recommendation by the U. S. Preventive Services Task Force 
(USPSTF; 2013) was for these individuals to be screened once in their lifetime even if 
they are asymptomatic.  The USPSTF deemed this a high-risk population and a 
recommendation was issued in 2013, making it a Grade B recommendation to be 
screened.  Previously, the USPSTF recommended against screening (Grade D 
recommendation) for adults not deemed being at a heightened risk of infection; 
insufficient evidence was found with regard to screening adults at high risk of infection 
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(Grade I recommendation).  Appendix A provides Grade Definitions and Levels of 
Certainty Regarding Net Benefit from the USPSTF.  There are various reasons why this 
particular population is at high risk: blood or blood product transfusions (as these 
products not screened for blood-borne diseases since universal screening was not 
implemented until 1992), intravenous drug use, and receiving unregulated tattoos.  The 
Hepatitis C virus is transmitted through blood products (transfusions), needle stick 
injuries or sharing needles for various reasons including drug use, and in health care 
settings due to reusing items or improper sterilization of equipment consisting mostly of 
needles or syringes.  The Hepatitis C virus can also be transmitted through sexual contact 
and childbirth; however, the virus is less commonly transmitted by these particular 
modes.  
 The Surgeon General, Boris Lushniak MD, provided his perspectives on testing 
the “Baby Boomer” population for HCV.  Dr. Lushniak (2014) pointed out that over the 
last 15 years, limiting testing to those individuals with specific risk factors and medical 
symptoms has yielded limited success: 
HCV is also the most common reason for liver transplantation and a leading cause 
of liver cancer, the fastest-rising cause of cancer-related death in the U.S. 
treatment for HCV is curative, however, and has been shown to reduce all-cause 
mortality among cured individuals. (p. 220) 
 
The USPSTF (2015) and the CDC (2016) recommend providing a one-time screening to 
adults born amongst this birth cohort for HCV.  With serious health complications that 
result from the Hepatitis C virus and a low level of diagnosis and management, it is 
prudent for this high-risk population, the Baby Boomers, to be tested one time in their 
lives.  This “recommendation enables medical providers to offer HCV testing to baby 
boomers routinely, without the barrier of discussing stigmatized risk behaviors” 
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(Lushniak, 2014, p. 220).  The Surgeon General urges this population be screened and 
tested for HCV to prevent diseases of the liver and possible death.  
 According to the CDC (2016), individuals in the early stages of HCV infection 
are typically asymptomatic but when symptoms of HCV do occur, they include fatigue, 
urine dark in color, fever, pale clay-colored stool, decreased appetite, abdominal pain, 
arthralgia, jaundice of the skin, nausea, and vomiting.  If a person presents with these 
particular signs and symptoms, it may be advantageous to test the individual for HCV. 
Having an increased alanine aminotransferase (ALT), a component of the liver function 
test, may also be indicative of the Hepatitis C virus, or at least another type of underlying 
disease of the liver, and should be checked if suspicious for HCV infection.  
Testing for the Hepatitis C virus is relatively simple.  Initially, a serum blood 
draw testing for anti-HCV antibody is performed.  If positive or equivocal, a serum HCV-
RNA (ribonucleic acid) blood draw is performed as a positive anti-HCV antibody does 
not necessarily confirm the diagnosis.  A positive anti-HCV only means the individual 
has been exposed to the Hepatitis C virus either currently or in the past.  The CDC (2013) 
recommends “an FDA-approved NAT [Nucleic Acid Testing] assay intended for 
detection of HCV RNA in serum or plasma from blood of at-risk patients who test 
reactive for HCV antibody should be used” (Testing for HCV RNA section, para. 1).  If 
the HCV-RNA is positive, the patient is diagnosed with active chronic Hepatitis C and 
may potentially receive treatment.  The sensitivity and specificity of the anti-HCV 
antibody test are 97% and 100%, respectively.  A sensitivity result of  
97% indicates that the screening test will detect at least 97% of individuals who 
have been exposed.  A specificity of 100% indicates that 100% of individuals 
without Hepatitis C had a negative screening test with no false-positive test 
results. (Joshi, 2014, p. 665)  
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 The sensitivity of the serum HCV-RNA test varies based on which test is 
performed.  An exact percentage could not be located; however, it is stated that “PCR 
[polymerase chain reaction] tests detect HCV RNA in the blood, which indicates current 
active infection.  This type of quantitative PCR test is very sensitive and can measure as 
few as 5-10 IU/mL” (Franciscus & Highleyman, 2014, p. 1).  The specificity of the HCV-
RNA tests is 99.98% (Tillmann, 2014, p. 6702).  With high sensitivity and specificity 
levels of the tests, it is prudent to screen individuals who are deemed at high risk in order 
to treat them and also decrease exposure to others who do not have HCV.  
Research Question  
 Q1 In adults born between the years 1945-1965 (P--Population), does a 
systematic population approach to Hepatitis C screening (I--Intervention) 
versus the provider assessing for high risk factors in the context of routine 
health and illness care (C--Comparison) result in increased screening (O--
Outcome)?  
 
Background and Significance of Project 
 The purpose of this capstone project was to implement Hepatitis C virus screening 
at the Eagle Ridge Medical and Fort Lupton clinics for patients born between the years 
1945 and 1965--the population also known as the Baby Boomer generation (see 
Appendix B for Statement of Mutual Agreement).  This generation has been deemed by 
the USPSTF (2015) as a high-risk population; therefore, it is not only prudent but also 
recommended to screen men and women of this population at least once in their lifetime.  
With successful treatment options available that currently yield a 90-100% cure rate, it is 
important to screen this population so they can begin a treatment regimen if warranted 
and not contraindicated. 
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 Hepatitis C virus is associated with multiple negative sequela and treatment is 
therefore prudent and advised.  Chronic “hepatitis C may eventually progress to cirrhosis, 
liver decompensation and hepatocellular carcinoma and many studies proved that HCV 
eradications reduce the risk of developing liver complications” (Calvaruso & Craxi, 
2016, p. 7).  Treatment methods currently exist for active chronic HCV, barring the 
patient does not have underlying liver disease.  Furthermore, treatment therapies vary 
based on the six known HCV genotypes and subsequent subtypes.  A gastroenterologist 
or hepatologist are specialty physicians who would initiate treatment therapy and monitor 
the effects of it.  Most commonly, HCV infection is affiliated with Genotype 1. 
Treatment-naïve patients who express Genotype 1 are initially treated with direct-acting 
antivirals (DAAs) and sometimes with or without ribavirin, depending upon the 
medication combination.  This treatment regimen is interferon-free (Chopra & Muir, 
2015, Treatment-naïve Patients section, para. 1).  It has been found that  
HCV exhibits an extraordinarily high degree of genetic diversity--substantially 
greater than that of the HIV-1 pandemic--creating a major challenge for the 
development of both HCV vaccines and pan-genotypic drug therapies. (Messina 
et al., 2015, p. 78) 
 
For this reason alone, one can see why it is important for genotype testing to be 
completed so the treatment may target the genotype and ensure a higher success rate of 
treatment.  Messina et al. (2015) stated:  
At present, the duration of treatment, cure rates, and the need for adjuvant 
interferon and ribavirin with the new DAA therapies remain dependent in part on 
HCV genotype and subtype.  Therefore, the development of national treatment 
strategies using DAA therapies requires a detailed understanding of the relative 
HCV genotype prevalence and subtypes. (p. 78) 
 
Direct-acting antiviral therapies generally produce more tolerable side effects than do 
peginterferon-alfa and ribavirin.  Particularly, second generation DAA therapies such as 
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the protease inhibitor simeprevir are generally well tolerated and have minimal side 
effects such as  
photosensitivity and rash [that] were reported in the simeprevir program with 
some serious reactions causing hospitalization.  Patients should be cautioned 
about this risk and instructed to use sun protective measures and limit sun 
exposure. (Pockros, 2015, Second-generation Protease Inhibitors section, para. 5) 
 
If the rash remains persistent or is severe in nature, it is recommended that the drug be 
discontinued.  Transient elevations in the bilirubin level have also been noted but no 
reports of liver toxicity have been identified.  Nausea and pruritus have also been 
documented as side effects of simeprevir.  
In addition to medication administration, Nguyen and Hu (2014) found,  
All patients with chronic HCV need education and counseling on measures which 
may be helpful in reducing progression of liver fibrosis. There are several studies 
that have reported associations between excessive alcohol use and the progression 
of liver fibrosis, development of HCC [hepatocellular carcinoma], and poorer 
response to treatment. (p. 27)  
 
If a patient is deemed to be an alcoholic, prior treatment of the alcoholism is prudent 
before initiating pharmacological therapy. 
 In addition, if a patient does have underlying liver disease, treatment options are 
still available; however, they are tailored to meet the needs of the patient in an attempt to 
decrease the risk of causing further damage to the liver.  Such treatment options include 
interferon-free, direct-acting antiviral medications for patients with compensated liver 
cirrhosis.  While “interferon-free regimens appear effective and safe for such patients, 
treatment should generally be undertaken in consultation with an expert in managing 
patients with cirrhosis” (Chopra & Muir, 2015, Patients with Cirrhosis section, para. 1). 
Medication options are  
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limited for patients with decompensated liver cirrhosis (ascites, hepatic 
encephalopathy, or gastroesophageal variceal hemorrhage), and antiviral 
treatment should only be undertaken by or in close consultation with an expert in 
the management of such patients, preferably at a transplant center. (Chopra & 
Muir, 2015, Patients with Cirrhosis section, para. 4)  
 
This population of patients also requires frequent laboratory and clinical monitoring and 
observation.  
 According to Joshi (2014), the “universal screening recommendation is based on 
the finding in the National Health and Nutrition Examination Survey [NHANES] that 
approximately 75% of persons with a positive screening test and chronic HCV infection 
were born during the years 1945-1965” (p. 665).  The NHANES is a chief program of the 
National Center for Health Statistics (NCHS) and is a part of the CDC (2014) with the 
responsibility of generating fundamental and health statistics for the nation (Introduction 
section, para. 1).  With current available treatment, screening the Baby Boomer 
generation for the Hepatitis C virus infection is recommended and pertinent.  Many 
individuals born within this timeframe have many years left to live if successfully treated; 
thus, they deserve the opportunity to be screened for HCV and treated accordingly. 
National and Regional Statistics 
Globally, the Hepatitis C virus infection is significant.  In 2005, it was estimated 
that “more than 185 million people had Hepatitis C virus (HCV) antibodies (prevalence 
of 2.8 percent)” (Chopra, 2015, Epidemiology section, para. 1).  Areas with high to low 
prevalence of HCV were identified.  Areas with high prevalence (>3.5%) included the 
Middle East, central and east Asia, and North Africa.  Areas with moderate prevalence 
(1.5 to 3.5%) included sub-Saharan Africa; south and southeast Asia; Andean, Central, 
and southern Latin America; Oceania; the Caribbean; western, central, and eastern 
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Europe; and Australasia including Australia, New Guinea, New Zealand, and nearby 
Pacific islands.  Areas with low prevalence (<1.5%) included tropical Latin America, the 
Asian Pacific, and North America (Chopra, 2015). 
In the United States, it is estimated that HCV is the most common blood-borne 
disease.  With approximately 17,000 new cases of HCV infection annually in the United 
States, it is clear the incidence is decreasing as there were approximately 230,000 cases 
per year in the 1980s.  The “overall incidence in 2010 was estimated to be 0.3 per 
100,000.  The decline relates primarily to reduced infections in injection drug users, a 
probable consequence of changes in injection practices motivated by a concern for HIV 
risk” (Chopra, 2015, United States section, para. 1).  After 1985, there were almost zero 
cases of HCV infection due to transfusions.  Deduced from analyses from the NHANES 
between the years 2003 and 2010 with regard to the United States, the predictable 
occurrence of  
antibodies to HCV was 1.3 percent (reflecting an approximate 3.6 million people 
with past or current HCV infection), and the estimated prevalence of HCV RNA 
positivity was 1.0 percent (reflecting an approximate 2.7 million people with 
chronic HCV infection). (Chopra, 2015, United States section, para. 4)  
 
The highest prevalence was noted in individuals born between 1945 and 1965.   
With this information alone, it is prudent to identify or accept this as a current, 
global health problem and one that needs to be addressed.  The Baby Boomer generation 
has a high prevalence of Hepatitis C, “sixfold the prevalence among all other adults” 
(Chopra, 2015, United States section, para. 7).  Screening for Hepatitis C virus infection 
is therefore a current recommendation from the USPSTF (2015) and should be 
implemented in clinical practice.  It is also worth noting that the researcher performed an 
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extensive search of the literature; however, national screening rates for HCV could not be 
obtained as available data did not exist.   
Financial Impact 
 The economic burden from Hepatitis C virus infection and its affiliated sequela is 
discussed from a national perspective of the United States.  As of 2012, the “total cost is 
estimated at $6.5 ($4.3-$8.4) billion and it will peak in 2024 at $9.1 ($6.4-$13.3) billion. 
The lifetime cost of an individual infected with HCV in 2011 was estimated at $64,490” 
(Razavi et al., 2013, p. 2164).  Yet, this cost is considerably higher amongst people who 
have a longer life expectancy.  Appendix C provides a graph showing the total prevalence 
and healthcare costs with 95% Confidence Intervals.  Razavi et al. (2013) stated: 
The majority of peak cost will be attributable to more advanced liver diseases – 
decompensated cirrhosis (46%), compensated cirrhosis (20%), and HCC (16%). 
The maximum cost associated with mild to moderate fibrosis (F0-F3) occurred in 
2007 at nearly $780 million. The cost associated with compensated cirrhosis is 
expected to peak in 2022 at $1.9 billion, while the peak cost for decompensated 
cirrhosis and HCC is predicted to occur in 2025, with annual costs in excess of 
$4.2 billion and $1.4 billion, respectively. (p. 2167)  
 
It should be noted that “F0-F3” correlates with stages of fibrosis.  Curry and Afdhal 
(2015) identified five stages: 
 F0: No fibrosis 
 F1: Portal fibrosis without septa 
 F2: Few septa 
 F3: Numerous septa without cirrhosis 
 F4: Cirrhosis (Stages of Fibrosis section, para. 1). 
 Compensated liver disease is identified as the first two stages of liver disease 
wherein the individual lacks varices or ascites in Stage 1 and is positive for varices and 
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negative for ascites in Stage 2.  Decompensated liver disease is identified as the third and 
fourth stages of liver disease wherein the individual might be positive or negative for 
varices and positive for ascites in Stage 3 and positive or negative for bleeding and 
positive for ascites in Stage 4 (Thornton, 2015, Approach to the Evaluation of Patients 
with Cirrhosis section, Figure 2). 
 As aforementioned, the lifetime cost of an HCV-positive person is approximately 
$64,490.  The lifetime cost of treating chronic hepatitis C sequela is boosted to $205,760 
($154,890-$486,890) when medical cost inflation is taken into consideration (Razavi et 
al., 2013, p. 2167).  Ultimately, it is clear to see that the Hepatitis C virus is burdensome 
and has a major financial impact in the United States.  
Theoretical Framework 
 The reach, efficacy, adoption, implementation, and maintenance (RE-AIM) 
framework adopted by Virginia Tech (2016) was utilized for the purpose of this capstone 
project.  The definitions of each component are discussed.  Reach refers to the number of 
individuals participating in the initiative and represents the number of people the 
intervention will affect.  Efficacy or effectiveness refers to the impact of the intervention 
on outcomes.  Adoption refers to the number of individuals willing to partake in the 
intervention.  Implementation refers to the “intervention agents’ fidelity to the various 
elements of an intervention’s protocol.  This includes consistency of delivery as intended 
and the time and cost of the intervention” (Virginia Tech, 2016, Implementation section, 
para. 1).  Maintenance refers to the extent of the initiative becoming routine in the 
practice.  The goal of this framework was to encourage various individuals including 
evaluators and policy-makers to be aware of the importance of and pay attention to 
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“essential program elements including external validity that can improve the sustainable 
adoption and implementation of effective, generalizable, evidence-based interventions” 
(Virginia Tech, 2016, What is RE-AIM section, para. 1).  The framework was originally 
devised in 1999 and is applied frequently to research and translation of evidence to 
practice.  In their article, Glasgow, Vogt, and Boles (1999) acknowledged a need for 
research methods that are devised to appraise the significance of interventions: 
Abrams and colleagues defined the impact of an intervention as the product of a 
program’s reach, or the percentage of a population receiving the intervention, and 
its efficacy (I = R X E).  We expand on this ‘RE’ (Reach X Efficacy) concept by 
adding 3 dimensions that apply to the settings in which research is conducted 
(Adoption, Implementation, and Maintenance: ‘AIM’) to more completely 
characterize the public health impact of an intervention. (p. 1323)  
 
This framework is also appropriate for evaluation of other areas related to health impact 
including a specific population.  However, there was no available research regarding 
application of the RE-AIM framework to HCV screening and limited available research 
with regard to other various diseases or disease screenings in general that were similar to 
this particular project.  
 The study conducted by Liu and Perkins (2015) was pertinent to the aim of 
increasing Hepatitis C virus screening rates as their study utilized the RE-AIM 
framework for evaluating an intervention to improve screening rates for another clinical 
screening recommendation.  Just as HCV is the leading cause of death from liver disease 
and the most common reason an individual would need a liver transplantation in the 
United States, colorectal cancer is also a leading cause of death.  The authors of this 
particular study included patients aged 50-74 years, which is also a USPSTF (2016) 
recommendation for colorectal cancer screening.  The lay cancer screening navigator 
contacted this birth cohort by phone and by letters in the mail if contact via phone was 
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not achieved.  Ultimately, the RE-AIM framework was utilized to evaluate the 
intervention and increased screening rates were identified after utilizing the lay cancer 
screening navigator.  The results of this particular study in relation to the RE-AIM 
framework are discussed.  
Reach: 91.9% of qualified patients were contacted by the lay cancer screening 
navigator; Effectiveness: At baseline, 28.6% of patients were already up to date 
on their colorectal cancer screenings and after six months, 40.5% were current 
and at 12 months, 42.2% were current; Adoption: All patients that were contacted 
stated they were receptive to the intervention; Implementation: Out of the 368 
mailed fecal test kits, 41% were returned (n=151) and 17.2% were positive 
(n=26); Maintenance: There was not a significant difference amongst patients 
who were current at the six and 12 month marks. (Liu & Perkins, 2015, p. 280)  
 
The RE-AIM model was expected to guide this project to achieve similar results with 
increased hepatitis C screening with a provider system reminder and counseling as 
opposed to not screening or counseling the patient at all.   
 In a systematic review, Compernolle et al. (2014) utilized the RE-AIM framework 
to explain the prospective public health impact of evidence-based multi-level 
interventions to enhance obesity-related behaviors in adults.  This review encompassed 
35 multi-level intervention studies with the following inclusion criteria: 
(1) the study included at least one outcome measure assessing obesity-related 
behaviours (i.e. dietary, physical activity and sedentary behavior); (2) the study 
collected data over at least one year; and (3) the study intervention was 
community-based, multi-level, and targeted adults. (Compernolle et al., 2014, p. 
149) 
 
Overall, 32 intervention studies failed to report on all five components of the RE-AIM 
framework and one-third of the intervention studies reported on the degree of 
effectiveness.  While most studies underreported their results within the RE-AIM 




The results of this systematic review are discussed.  
 Reach--58% of the population was aware of the intervention.  
 Effectiveness--89% of studies documented encouraging obesity-related 
behavioral (71%) or overweight and obesity-related physiological results 
(34%).  Some of the studies reported on behavioral outcomes including 
physical activity or inactive behavior and other studies reported on dietary 
behaviors.  
 Adoption--adoption of interventions was stated in all 35 studies.  
 Implementation--entirety of implementation was stated in 29% of the studies 
(n = 10) and in one study, implementation percentages varied from 17% for 
widespread personal contacts with residents to 91% for the lending and 
selling of pedometers.  
 Maintenance--at the individual level, eight interventions stated their health 
behavior at a minimum of six months after the study period.  At the level of 
the organization, 16 interventions were continued until October of 2013.  
This type of utilization of the RE-AIM framework is certainly not identical to 
HCV screening; however, it is significant to discuss such studies that utilize this 
framework to prove it does have benefit and is important in reflecting how research and 
evidence are translated into practice.   
With regard to this capstone project, to reach the intended population (adults born 
between 1945 and 1965, which represents 1,906 patients), an alert in Micro Development 
Services Incorporated (MDS), a system utilized within the electronic health record (EHR) 
at Eagle Ridge Medical and Fort Lupton clinics, was created to alert the four physicians 
15 
 
and act as a cue to action that the patient should be informed about Hepatitis C virus 
screening recommendation if born between the years 1945 and 1965.  The alert was a 
screening reminder and was generated as a task in the EHR for providers when they 
opened the patient’s chart.  Informative letters intended to notify the patient of the 
USPSTF’s (2015) recommendation to be screened for a blood-borne disease were mailed 
to individuals born within this specific timeframe to give them an opportunity to be 
screened in case they did not have an appointment with their provider over the next 
several weeks.  
Effectiveness was evaluated based on how many individuals born between the 
years 1945 and 1965 were screened for the Hepatitis C virus after the screening trigger 
interventions were implemented at the clinic.  A chart audit was performed to establish 
the current screening rate of this Baby Boomer population prior to the implementation 
date of the screening trigger alert for the Hepatitis C virus and sending the informative 
postal letters to this population; the chart audits took place on 5% of the patients (n = 95).  
Adoption of the intervention for this capstone project was achieved.  Four 
physicians and staff members of the clinic, including the office manager, deemed this 
project as feasible and also valuable to the clinic.  A meeting was held with regard to this 
capstone project and discussion ensued.  The providers agreed this project was important 
and also agreed the clinic had not been implementing any type of standard for screening 
the Baby Boomer generation.  The providers and staff were in agreement that the 
researcher could move forward with the project.  
Implementation of the intervention was achieved in April of 2016 following 
Institutional Review Board (IRB) approval (see Appendix D).  With encouragement and 
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support from the providers, the student anticipated adherence from the providers to 
ensure the patients were being screened.  Dissemination of the message occurred in 
person as to when the providers should start screening the patients; the providers had 
already been educated on what the alert would look like within the EHR system.  The 
alert cannot be turned off by the provider and appears every time the patient’s chart is 
opened.  Willingness to change provider practice and implement HCV screening was 
gained prior to implementation through a meeting held with the physicians.  Provider 
compliance with the screening alert was assessed after the first week of implementation. 
Simply, the researcher discussed with each of the providers seven calendar days after the 
screening alert for HCV was created in the EHR system to gather information as to 
whether or not they were addressing the screening alert and subsequently screening the 
Baby Boomer population.  All four physicians (100%) stated they had been screening this 
patient population and that it was helpful the EHR alert was implemented as a reminder. 
The researcher addressed 1,906 envelopes and worked closely with the office manager to 
ensure the postal letters were sent to patients born between the years 1945 and 1965.  Per 
the office manager, the office assumed the cost of the postage and envelopes; letters were 
mailed in April of 2016 following IRB approval. 
Maintenance of the intervention was evaluated at the initiation of the screening 
implementation and throughout subsequent weeks.  Long-term effects of the intervention 
were evaluated and the researcher conveyed success of the specified intervention as 
screening rates increased.  Discussion with the providers ensued on an as-needed basis; 
the researcher interviewed the providers after the screening was implemented to ensure 




With high prevalence of the Hepatitis C virus amongst the Baby Boomer 
generation (those born between the years 1945 and 1965), it was evident that screening 
for the infection or for the virus should be performed on this population.  There are 
various reasons as to why this population was deemed high-risk by the USPSTF (2015) 
including blood or blood product transfusions prior to 1992 when universal screening was 
implemented, receiving unregulated tattoos, or participating in intravenous drug use. 
Regardless, a majority of the adults in this population might have an extended life span.  
With current treatment available, it was prudent for them to be screened so treatment 
might be initiated in a timely manner.  Current treatment regimens yield an extremely 
high success cure rate of 90-100% and therefore should be taken advantage of if a patient 
is found to be HCV-positive.  Overall, it is advantageous for this population to be 
















Literature Review Parameters 
 A review of the literature was performed on articles related to Hepatitis C virus 
for the purpose of this capstone project.  Identified databases and guideline literature 
included the Centers for Disease Control and Prevention, the U.S. Preventive Services 
Task Force, UpToDate, World Health Organization, Medline, ProQuest Nursing & Allied 
Health Source, and PubMed.  The review of literature spanned the years from 1999-2016. 
Keywords included Hepatitis C virus, active Hepatitis C, chronic Hepatitis C, Hepatitis C 
screening, Hepatitis C treatment, Hepatitis C genotypes, Liver cirrhosis, Perinatal 
Hepatitis C, and Hepatitis C management.  All of the researched articles and studies were 
credible and from well-known, evidence-based databases, journals, and websites.  Types 
of studies included randomized controlled trials, systematic reviews, and quantitative 
studies.  All articles, studies, and guidelines were published in English.  
Summary, Critical Review, and Synthesis of Literature 
 The USPSTF (2015) recommended that adults born between 1945 and 1965 be 
screened once in their lifetime for the Hepatitis C virus.  This guideline exists because 
most of those patients with the Hepatitis C virus are in this specific general population.  
Thus, it is prudent to screen this high-risk population since curative treatment is 
available.  The USPSTF was founded in 1984 and is comprised of a  
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volunteer panel of national experts in prevention and evidence-based medicine. 
The Task Force works to improve the health of all Americans by making 
evidence-based recommendations about clinical preventive services such as 
screenings, counseling services, and preventive medications. (USPSTF, 2016, 
para. 1) 
  
Such experts included those from various backgrounds including family medicine, 
internal medicine, behavior health, obstetrics and gynecology, nursing, and pediatrics.  
Their recommendations were devised after a thorough review of current peer-reviewed 
evidence with intentions of assisting clinicians and patients to decide together whether a 
preventive service was suitable for the needs of a patient (USPSTF, 2016, para. 2).  The 
USPSTF is closely affiliated with the Agency for Healthcare Research and Quality 
(AHRQ) and has been since 1998.  The AHRQ has been “authorized by the U.S. 
Congress to convene the Task Force and to provide ongoing scientific, administrative, 
and dissemination support to the Task Force” (USPSTF, 2016, para. 4).  Annually, the 
Task Force reports to Congress with regard to “critical evidence gaps in research related 
to clinical preventive services and recommends priority areas that deserve further 
examination” (USPSTF, 2016, para. 5).  
The CDC (2015) is another credible resource that is renowned and evidence-
based: 
As the nation’s health protection agency, CDC saves lives and protects people 
from health threats.  To accomplish our mission, CDC conducts critical science 
and provides health information that protects our nation against expensive and 
dangerous health threats, and responds when these arise. (CDC, 2015, CDC’s 
Mission section, para. 2) 
 
This governmental resource offers clinicians up-to-date information regarding 
recommendations, guidelines, useful information about the diseases such as transmission 
patterns and risk factors, and incidence or prevalence of various diseases including the 
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Hepatitis C virus.  A “recent CDC analysis of death certificate found that HCV-
attributable deaths increased significantly between 1999-2007.  CDC estimates that there 
were 15,106 deaths caused by HCV in 2007” (CDC, 2016, How Many Deaths Can Be 
Attributed to Chronic HCV Infection? section, para. 1).  The CDC also reports various 
testing methods and recommendations on vaccinations.  Overall, this resource offers a 
multitude of relevant and important information regarding a plethora of diseases from a 
national and international standpoint.  
 Founded in 1948, the World Health Organization (WHO; 2016) is another vital 
resource whose primary function is to direct and coordinate international health within 
the system of the United Nations.  Their focal areas of work include “health systems, 
promoting health through the life-course, noncommunicable diseases, communicable 
diseases, corporate services, and preparedness, surveillance and response” (WHO, 2016, 
What We Do section, para. 1).  The WHO understands that “early diagnosis can prevent 
health problems that may result from infection and prevent transmission of the virus. 
WHO recommends screening for people who may be at increased risk of infection” 
(WHO, 2015, Getting Tested section, para. 1).  Recognition of high-risk populations is 
important to understand the magnitude of testing so individuals may be treated if 
warranted.  The WHO goes on to mention primary, secondary, and tertiary prevention. 
While there is no current vaccination for the Hepatitis C virus, prevention is focused on 
decreasing exposure to the blood-borne virus through good hand washing, proper 
disposal of sharp objects including needles, proper education regarding condom use, and 
thorough training of health professionals (WHO, 2015, Prevention section, para. 2). 
Secondary and tertiary preventions include education and counseling with regard to 
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treatment options and the importance of immunizations against Hepatitis A and B to 
avoid coinfection of these viruses to protect the person’s liver.  These types of prevention 
also include prompt and appropriate medical management, including antiviral therapy if 
warranted, and consistent monitoring for early identification of chronic liver disease 
(WHO, 2015, Prevention section, para. 3). 
 UpToDate (2016) is another major resource that offers a wealth of information for 
providers: 
UpToDate is an evidence-based, physician-authored clinical decision support 
resource which clinicians trust to make the right point-of-care decisions.  More 
than 6,300 world-renowned physician authors, editors, and peer reviewers use a 
rigorous editorial process to synthesize the most recent medical information into 
trusted, evidence-based recommendations that are proven to improve patient care 
and quality. (para. 1) 
 
The resource is unbiased as funding from pharmaceutical companies, commercial 
entities, and medical device manufacturers is not accepted.  The resource has been 
utilized by more than 90% of U.S. academic medical centers and approximately 1.1 
million providers in 180 countries and is affiliated with improved outcomes (UpToDate, 
2016, para. 1). As aforementioned, this resource offers useful information regarding 
HCV. 
 In their article, Chopra and Pockros (2015) provided current and relevant 
information about various treatment options specific to the genotype and other patient 
factors.  Multiple “studies have suggested that these regimens, even at their introductory 
high cost, are cost-effective for many populations, including those with genotype 1 
infection or advanced fibrosis, because of their superior efficacy in clinical trials” 
(Chopra & Pockros, 2015, Treatment Options section, para. 2).  After 12 weeks of 
treatment cessation, viral load should be checked to evaluate virologic response.  While a 
22 
 
“sustained virologic response (SVR) was traditionally defined as an undetectable viral 
level at 24 weeks post-treatment, an undetectable level at 12 weeks post-treatment is 
generally maintained through week 24” (Chopra & Pockros, 2015, Assessing a Treatment 
Response section, para. 1).  As aforementioned, management for the treatment-naïve 
patient with HCV Genotype 1 should include interferon-free therapies with DAAs with or 
without ribavirin depending on the specific combination.  Chopra and Muir (2015) also 
included management for treatment-experienced individuals.  This type of patient has  
failed prior treatment with peginterferon and ribavirin and are initiating antiviral 
therapy now…The options are the same as for treatment-naïve patients and are 
ledipasvir-sofosbuvir, ombitasvir-paritaprevir-ritonavir plus dasabuvir with or 
without ribavirin, simeprevir plus sofosbuvir, and daclatasvir plus sofosbuvir. 
(Chopra & Muir, 2015, Treatment-experienced Patients section, para. 1) 
 
 In his article, Pockros (2015) provided current, evidence-based information 
regarding treatment of HCV.  He found second generation DAAs (protease inhibitors) 
were proven to be better tolerated by patients, they were affiliated with more transient 
side effects, and they had been proven to be more effective with treating HCV genotype 
1--the most common genotype in the United States.  In their systematic review, Messina 
et al. (2015) stated, “It is important to note that the most prevalent genotype in developed 
economies (genotype 1) is also the most prevalent globally and should be well served by 
interferon-free regimens of second-generation DAA therapies with viral eradication rates 
of >90%” (p. 83).  It is true that “treatment of chronic hepatitis C has evolved over the 
last two decades, with 90%-100% of individuals now being cured” (Joshi, 2014, p. 664).  
 Hepatitis C viral infection is prominent globally and in the United States; it is 
particularly prevalent amongst the Baby Boomer generation.  The USPSTF (2015) 
recommends this population (born between 1945 and 1965) be screened for HCV at least 
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once in their lifetimes.  The American Association for the Study of Liver 
Diseases/Infectious Diseases Society of America (2015) supported this recommendation 
with a rating of Class I, Level B (see Appendix E for classifications and descriptions).  In 
an article for The Journal for Nurse Practitioners, Hande (2014) also supported the 
recommendation and stated,  
A disproportionately high prevalence of HCV infection and HCV-related disease 
is associated with these adults [“Baby Boomers”].  They are at greater risk for 
hepatocellular carcinoma and HCV-related liver disease and comprise 73% of 
HCV-associated mortality. (p. 64) 
  
The author goes on to mention that a study conducted by “Liu et al. concluded that the 
birth cohort screening provides nearly twice the benefit of risk-based screening alone” (p. 
65).  
 Testing for the Hepatitis C virus includes anti-HCV antibodies and subsequent 
HCV-RNA if the anti-HCV antibody test is positive or equivocal.  The Ochsner Journal, 
a peer-reviewed publication, has “several processes in place to ensure the Journal’s 
compliance with the Committee on Publication Ethics (COPE) and the International 
Committee of Medical Journal Editors ethics guidelines” (Amedee, 2015, p. 397).  This 
journal is known to be credible and reliable and is “committed to the highest levels of 
professional standards and publication ethics and requires the same commitment from its 
authors and peer reviewers” (Amedee, 2015, p. 397).  Utilized for the purpose of this 
capstone, this article relayed pertinent information regarding screening and testing for 
HCV and its cost-effectiveness.  
Joshi (2014) reported: 
It is often difficult to know the exact cost of medical tests because of the lack of 
transparency and negotiated pricing by insurance companies.  Nevertheless, the 
screening test for hepatitis C, anti-HCV antibody, offered by testing facilities or 
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advertised on the internet costs $45-$80 for uninsured individuals and less when 
covered by insurance. (p. 666) 
 
Truly, this cost is nominal when one considers the big picture of the Hepatitis C virus and 
its comorbidities including liver disease and hepatocellular carcinoma (HCC).  With 
proper counseling and education, a clinician can likely assist the patient in viewing the 
big picture as opposed to looking at the issue from a perspective of less significance.  
When one considers the cost of the disease burden of HCV itself, the cost of 
testing pales in comparison.  The quantitative study by Razavi et al. (2013), as 
aforementioned, was found to be credible but did have some limitations:   
The model does not explicitly account for alcohol consumption and metabolic 
syndrome.  Frequent heavy intake of alcohol significantly increases fibrosis 
progression, and accelerated disease progression has been associated with 
metabolic syndrome. (pp. 2168-2169)  
 
 Likely, the costs associated with HCV would be even higher if these aspects were 
taken into account as alcohol is damaging to the liver and even more so when an 
individual has underlying liver disease from HCV.  Razavi et al. (2013) stated: 
A limitation of prevalence measures used in this analysis is that high prevalence 
populations may be undersampled through the NHANES.  In particular, 
undersampling of veterans, prisoners, and the homeless would result in 
underestimation of the current prevalence, future disease, and cost burden. (p. 
2169) 
 
Ultimately, the costs are most likely higher than anticipated or estimated due to 
the sequela of HCV.  Healthcare costs are projected to rise as the incidence of advanced 
liver disease increases.  Razavi et al. (2013),  
Lifetime healthcare costs for an HCV-infected person are significantly higher than 
for noninfected persons, and the expected cost is higher among populations with a 
higher life expectancy.  Finally, it is possible to substantially reduce HCV 
infection in the US through active management (p. 2169)  
25 
 
Therefore, it is prudent to be screened and treated for HCV if tested positive to decrease 
associated costs and increase years of life.  
Several studies used the RE-AIM framework to evaluate screening procedures.  
Glasgow, Vogt, and Boles (1999) indicated, “Public health interventions should be 
evaluated more comprehensively than has traditionally been done.  Dimensions such as 
reach, adoption, and implementation are crucial in evaluating programs intended for 
wide-scale dissemination” (p. 1325).  Evaluation of a project or implementation change is 
valid and necessary; often utilized is the RE-AIM framework (Virginia Tech, 2016).  In 
their systematic review, Gaglio, Shoup, and Glasgow (2013) identified 71 articles “after 
excluding nonempirical articles, case studies, and commentaries” (p. e38), most of which 
mentioned obesity, physical activity, and disease management.  The RE-AIM framework 
assisted in translating various types of research, including prevention and disease 
management, into meaningful outcomes.  Gaglio et al. stated:  
RE-AIM was initially designed to help evaluate interventions and public health 
programs, to produce a more balanced approach to internal and external validity, 
and to address key issues important for dissemination and generalization.  Over 
time, it has expanded to include more diverse content areas, and is used in 
planning in addition to reporting reviews.  More recently, it has been applied to 
policies and community-based multilevel interventions, as well as to reduce 
health disparities. (e38) 
 
Initially, the RE-AIM framework was utilized by a group of investigators predominantly 
to assess research of health behaviors.  Currently, it is used in the preparation stages to 
assess development, report outcomes, and appraise the literature in various health areas 
(Gaglio et al., 2013, p. e45).  
A quantitative study by Liu and Perkins (2015) indicated screening rates were 
increased after implementation of the lay cancer screening navigator.  This is not unlike 
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this researcher’s capstone project in utilizing providers in screening patients born 
between 1945 and 1965 for HCV.  The RE-AIM framework (Virginia Tech, 2016) was 
utilized for their particular study and yielded success, particularly the efficacy 
component.  Of 1,394 qualified patients in this study, the lay cancer screening navigator 
communicated with 91.9% of the patients.  At “baseline, 28.6% of patients were current 
on their colorectal screening, 40.5% at 6 months, and 42.2% at 12 months” (Liu & 
Perkins, 2015, p. 280).  It was clear to see that implementation of this resource, the lay 
cancer screening navigator, increased screening rates in the population of adults between 
50 and 74 years of age. Utilization of the RE-AIM framework assisted in appraisal of the 
significance of interventions.  
A systematic review conducted by Compernolle et al. (2014) identified 35 
different intervention studies and applied the RE-AIM framework (Virginia Tech, 2016) 
to them to ensure the authors of the studies met the components of this framework.  
While not all of the intervention studies were found to meet all five components, it was 
still deemed by the authors of this systematic review that the RE-AIM framework was 
positively evaluated with regard to short-term behavioral changes but would likely need 
more information regarding external cogency and “sustainability in order to take 
informed decisions on the choice of interventions that should be implemented in real-
world settings to accomplish long-term changes in obesity-related behaviours” 
(Compernolle et al., 2014, p. 147).  Although this systematic review did not identify 
screening rates of a particular disease and lacked positive comparison to this researcher’s 
current project and aim of identifying increased HCV screening, it was still beneficial to 
observe how the RE-AIM framework was utilized amongst various studies. 
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The literature was limited on EHR alerts and mailing informative letters for 
Hepatitis C virus screening but there was pertinent literature with regard to other various 
screening measures.  The randomized controlled trial conducted by Sequist, Zaslavsky, 
Marshall, Fletcher, and Ayanian (2009) provided validation for EHR alerts and mailed 
reminders with subsequent increases in screening rates found in their study.  This study 
was conducted because screening for colon cancer, a leading cause of death, is a national 
recommendation for adults 50 years and older; it is estimated that only about 60% of 
eligible candidates are current on their screenings.  Participants in this study “included 
21,860 patients aged 50 to 80 years who were overdue for colorectal cancer screening 
and 110 primary care physicians” (Sequist et al., 2009, p. 364).  Creating an EHR alert 
and mailing letters with regard to the importance of screening proved to increase rates of 
screenings.  Sequist et al. stated: 
Screening rates were higher for patients who received mailings compared with 
those who did not (44.0% vs 38.1%; P < .001).  The effect increased with age: 
+3.7% for ages 50 to 59 years; +7.3% for ages 60 to 69 years; and +10.1% for 
ages 70 to 80 years (P=.01 for trend).  Screening rates were similar among 
patients of physicians receiving electronic reminders and the control group 
(41.9% vs 40.2%; P=.47).  However, electronic reminders tended to increase 
screening rates among patients with 3 or more primary care visits (59.5% vs 
52.7%; P=.07).  Detection of adenomas tended to increase with patient mailings 
(5.7% vs 5.2%; P=.10) and physician reminders (6.0% vs 4.9%; P=.09). (p. 364) 
 
Overall, it was found that “mailed reminders to patients are an effective tool to promote 
colorectal screening, and electronic reminders to physicians may increase screening 
among adults who have more frequent primary care visits” (Sequist et al., 2009, p. 364).  
 In another randomized controlled trial, Ayanian, Sequist, Zaslavsky, and Johannes 
(2008) aimed to discover if mailed reminders to physicians would increase their patients’ 
overdue colonoscopies.  Not unlike an EHR alert for HCV, physicians were reminded of 
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important screening opportunities for their patients.  This study included 141 physicians 
in Massachusetts in 2006 and 717 patients “who had colorectal adenomas removed 
during 1995 through 2000 and no follow-up colonoscopy identified via automated review 
of electronic records through March, 2006” (Ayanian et al., 2008, p. 762).  Ayanian et al. 
stated: 
The use of colonoscopy and detection of new adenomas or cancer were assessed 
at 6 months by a blinded medical record review in all patients.  Among 358 
patients whose physicians received reminders, 33 (9.2%) patients underwent 
colonoscopy within 6 months, compared with 16 (4.5%) of 359 patients whose 
physicians did not receive reminders (P=0.009).  In prespecified subgroups, this 
effect did not differ statistically between 2 primary care networks, elderly and 
nonelderly patients, or women and men (all P>0.60 by Breslow–Day test).  New 
adenomas or cancer were detected in 14 (3.9%) intervention patients and 6 (1.7%) 
control patients (P=0.06), representing 42.4% and 37.5% of patients who 
underwent colonoscopy in each group, respectively.  Despite using advanced 
electronic health records to identify eligible patients, 22.5% of enrolled patients 
had a prior follow-up colonoscopy ascertained only by visual record review, and 
physicians reported 27.9% of intervention patients were no longer active in their 
practice. (p. 762) 
 
Ultimately, for patients who were diagnosed with colorectal adenomas, mailing 
reminders to their physicians proved to increase colonoscopy screenings.  
Summary 
 This extensive literature review provided evidence-based, relevant, and current 
information regarding the Hepatitis C virus.  It is clear that HCV is a current problem 
both globally and nationally and a virus affiliated with six different genotypes. The HCV 
genotype 1 is the most prevalent in the United States and has been found to respond well 
to treatment with second generation DAAs.  These pharmaceutical interventions 
generally yield more transient and therefore more tolerable side effects with a 90%-100% 
cure rate.  Screening the identified birth cohort would be advantageous since prevalence 
of HCV amongst this population currently far exceeds any other birth cohort.  While the 
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literature was limited with regard to specific increases in HCV screening rates via letters 
or alerts in the EHR, literature did exist for other various screenings including colorectal 
cancer screening, which yielded higher rates of screening when letters were mailed to 
patients or when a patient attended three or more visits with their primary care providers.  
Project Objectives 
 The main objective of this project was to increase providers’ awareness of the 
USPSTF’s (2015) recommendation to screen for HCV with the focus on subsequent and 
projected increased screening rates measured through the EHR of the identified birth 
cohort (adults born between 1945 and 1965).  Increasing providers’ awareness of this 
recommendation is important so they understand the magnitude of HCV screening for the 
identified birth cohort as 75% of adults with HCV were born during this time frame. 
Eagle Ridge Medical and the Fort Lupton clinic currently do not have a standardized 
approach to screen for HCV. After a meeting with the providers of the clinic, it was 
brought to this researcher’s attention that only select patients had been screened and 
generally only if they had physiological symptoms that warranted the screening measure.  
High-risk behavioral history questions of the patients such as intravenous drug or if the 
patient had received a blood or blood product transfusion before the year of 1992 were 
also not asked on a regular basis.  It is important to understand the reasoning behind 
screening this birth cohort as adults in this particular birth cohort are “5 times more likely 
than other adults to be infected.  In fact, 75% of adults with Hepatitis C were born in 
these years” (CDC, 2012, This Hepatitis C Testing Recommendation Was Made Because 
section, para. 1).  
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 The objective was carried out by creating an alert reminder in the EHR for 
providers to screen for HCV if the patient was born in the years 1945 to 1965.  
Informative letters notifying the patient of the USPSTF’s (2015) recommendation to be 
screened for a blood-borne disease were also mailed to the Baby Boomer generation in 
case they had not made an appointment at the clinic over the next several weeks and 
would not have been given the opportunity to be screened for HCV otherwise.  With the 
high accuracy of testing results and current treatment available, screening this high-risk 
population is important and warranted.  Identifying seropositive individuals not only 
gives the potential to treat and prolong a certain individual’s life but also provides an 
opportunity for education regarding transmission and how to decrease the likelihood of 




















Evidence-Based Project Plan 
 This capstone project was implemented due to the fact that the Eagle Ridge 
Medical and Fort Lupton clinics did not currently have a standardized implementation 
process of screening all adults born between 1945 and 1965 for HCV as recommended by 
national screening guidelines; 100% of the physicians at this clinic (N = 4) agreed to take 
part in this project by screening the specified patient population for HCV.  The purpose 
of this project was to increase screening rates of HCV in this birth cohort by 
implementing an alert in the EHR (a screening reminder to act as a cue to action for the 
providers) for this birth cohort, which prompted providers to screen and counsel these 
patients on HCV.  Informative postal letters indicating the patient was recommended by a 
group of national experts to be screened for a blood-borne disease were also mailed to 
this birth cohort if an appointment was not achieved during the initial project 
implementation to ensure this entire population of Eagle Ridge Medical and the sister 
clinic in Fort Lupton was being reached.  The providers at Eagle Ridge (who are also 
affiliated with the Fort Lupton clinic as two are the same providers at both clinics) 
requested the letter be generic and it included the national recommendation from the 
USPSTF (2015) to be screened for a blood-borne disease (see Appendix F for the letter).  
Discussion with the office manager and providers occurred prior to implementation in the 
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EHR to clarify the practice change and discuss its significance.  This researcher provided 
the background of the literature review to exemplify the evidence-based research 
supporting this practice change.  A fact sheet (see Appendix G) from the CDC (2012) 
was also made available to patients who were counseled or screened for HCV.  This fact 
sheet was available to patients in the lab of the clinic where they underwent a peripheral 
blood draw for testing.  
 The USPSTF is a government entity that guides medical practices and providers. 
Eagle Ridge Medical and the sister clinic in Fort Lupton are not exempt from this and are 
clinics with a goal to adopt standards of practice to ensure the best possible care is being 
delivered to their patients.  Since Hepatitis C virus screening is a Grade B 
recommendation (USPSTF, 2013) and something not currently being done at Eagle Ridge 
Medical and the Fort Lupton clinics, the office manager approved this practice change 
and believed it to be pertinent.  Other renowned resources include the CDC (2016) and 
the WHO (2015), which also support the screening recommendation from the USPSTF 
(2015).  The Baby Boomer generation has been proven to be a high-risk population and a 
one-time screening is recommended.  Current pharmacological treatment regimens exist 
and yield high success rates of viral eradication.  Therefore, it behooves Eagle Ridge 
Medical and the Fort Lupton clinic to offer HCV screening to this birth cohort that utilizes 
their clinic for medical care and refers for treatment if warranted.  
Timeline 
The timeline for this capstone project was as follows: 
 Meeting with office manager and four providers at Eagle Ridge Medical and 
the Fort Lupton clinics to increase awareness of USPSTF’s (2015) 
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recommendation and EHR implementation of screening reminder for HCV--
February 2016 
 Proposal defense/IRB approval of capstone--March 2016/April 2016 
 Mail informative letters to patients (following IRB approval)--April 2016 
 CDC (2012) fact sheet handouts available in the lab of the clinic--April 
2016 
 Chart audit prior to implementation of screening reminder in EHR and 
mailing of informative letters to obtain baseline screening rate--April 2016 
 Chart audit after implementation of screening reminder in EHR and 
informative letters mailed to obtain subsequent screening rate--May 2016 
 Program development--March to June 2016 
 Capstone defense--June 2016 
Resources, Personnel, Technology, and Budget 
 Personnel resources include one office manager, four physicians, and five medical 
assistants (MAs).  The office manager is in charge of ensuring successful implementation 
of the screening reminder into the EHR (see Appendix H for an example of a typical 
screening reminder) and also ensures implementation of the flow sheet.  Note that the 
screening reminder example in Appendix H is of a test patient and does not identify an 
actual patient.  The screening reminder for HCV screening for the providers says 
“Hepatitis C Screening.”  The flow sheet is a table within the EHR that informs the 
provider if the patient has or has not been screened or if the patient refuses screening.  
The physicians execute counseling and screening methods of the identified birth cohort 
and acknowledge the screening reminder in the EHR.  The medical assistants support the 
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practice change by executing the standing order for the anti-HCV antibody test 
implemented for patients who requested testing based on the recommendations in the 
informative letter.  In this case, the patient does not need to schedule an appointment with 
their provider (unless they desire to do so) and could simply come to the clinic for the 
blood draw.  All four physicians (100%) agreed upon implementation of a standing order 
for the MAs to draw the anti-HCV antibody in the lab.  The CDC fact sheet was also 
disseminated to patients in the lab per request of the office manager and physicians. 
Normal results will be mailed to the patients.  Patients who test positive for HCV will be 
called and instructed to make an appointment with their provider.  Positive results will 
not be relayed over the phone as the patient will be instructed to come to the clinic for an 
appointment.  The administrative staff of the clinic will ensure each new patient 
completes the Acknowledgement of Notice of Privacy Practices and HIPAA Consent 
upon their initial appointment that is updated annually at the clinic by the patient (see 
Appendix I for a copy of the form).  While there is a section on the form that identifies 
the patient’s consent to discuss care/test results, sensitive information such as results 
from HCV testing are not disclosed.   
Other sensitive information not disclosed included but was not limited to human 
immunodeficiency virus (HIV) results, sexually transmitted disease (STD) results, or 
pregnancy test results.  A section on this form also gives the patient a “yes” or “no” 
option with regard to whether confidential information can be left on voice mails or 
answering machines.  However, sensitive information or results such as the ones 
aforementioned are not left on a voice mail or answering machine regardless of the 
patient’s consent on this form.  To ensure the staff is speaking to the correct patient 
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before relaying information in general, the patient is asked his/her full name and date of 
birth and the staff verifies the information on the patient’s chart in the EHR before any 
results are given.  The author of this project protected identity of patients by not 
disclosing any protected health information (PHI) including name, date of birth, 
diagnosis, social security number, address, or any other sensitive information she had 
access to from the EHR.  The utilized data for collection purposes were strictly limited to 
a percentage of the population screened prior to and after implementation of the EHR 
alert (screening reminder) and did not contain any PHI of any nature.  
 Additional equipment other than what was already stocked at Eagle Ridge 
Medical and the Fort Lupton clinics was not necessary.  The labs at the clinics were 
already stocked with the appropriate materials needed for HCV testing including 
tourniquets, serum tubes, venipuncture needles, vacutainers, gauze, and tape.  The clinic 
utilizes the EHR system; costs for creating an alert for the HCV screening reminder and 
the flow sheet were assumed by the clinic.  
 Items necessary for collecting of blood for the HCV tests were already available 
in the setting and further costs were not projected to increase as the clinics had a plethora 
of these specific supplies.  The only projected cost of this project was the informative 
postal letters mailed to patients born between the years 1945 and 1965.  The current cost 
of a stamp was $0.49 and the office manager agreed to purchase these stamps with the 
budget from the clinic.  While exact costs for these items were unavailable due to the fact 
that items were mailed from the main affiliated hospital, Platte Valley Medical Center, 
costs were estimated to be less than $2,000 and were assumed by Eagle Ridge Medical 
and its sister clinic in Fort Lupton.  Costs were also taken into account regarding letters 
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that would be mailed notifying patients of all normal HCV results.  Currently, 1,906 
persons born between 1945 and 1965 are patients of Eagle Ridge Medical at the Brighton 
and Fort Lupton locations.  The Fort Lupton location is being used as well because two of 
the physicians at Eagle Ridge Medical in Brighton float to this clinic during the week and 
therefore many patients utilize both clinics.  Again, while it is difficult to produce an 
exact cost of the anti-HCV antibody test for an insured patient, an uninsured patient 
would assume $47.00.  This researcher obtained the cost of the test from the billing 
department at Eagle Ridge Medical and the Fort Lupton clinics. 
 Additionally, no risks or threats were affiliated with this capstone project. 
Benefits of implementation of this project included increased provider awareness of the 
USPSTF (2015) recommendation to screen the Baby Boomer population for HCV and 
the significance of the screening as current treatment is available that yields a high 
success cure rate. 
Evaluation Plan 
 Evaluation of the plan, which included two phases (pre- and post-intervention of 
the project), was assessed by first performing a chart audit of 5% of the 1,906 established 
patients at Eagle Ridge Medical and the Fort Lupton clinics (n = 95) and a chart audit of 
patients seen at the clinics six weeks prior to the implementation date who were born 
between 1945 and 1965 to establish a baseline screening rate for HCV among eligible 
patients. This occurred prior to implementation of the alert reminder in the EHR and 
mailing of informative letters to patients.  This number was compared to a chart audit of 
95 patients, representing 5% of the 1,906 established patients; these patients were seen at 
the clinics six weeks after the implementation date screened for HCV, after 
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implementation of the alert reminder in the EHR, and after mailing informative letters to 
this birth cohort.  This researcher tracked absolute screening results of both the alert 
reminder in the EHR and mailing of letters and therefore did not discriminate between the 
two methods in the results section.  It was this researcher’s assumption that screening 
rates of patients for HCV would increase in this birth cohort after implementation of the 
alert reminder in the EHR was created and informative letters were mailed.  When a 
patient was screened for HCV, the provider or administrative staff updated information 
within the EHR system to prevent duplicative screening of patients if they came to the 
clinic for subsequent visits after having been screened once before.  
 This researcher protected each patient’s identity during the chart audits (prior to 
and after this project implementation) by ensuring the audits were done at the clinic 
utilizing only a clinic-approved computer and ensuring the audits were being performed 
in an area from which patients were restricted.  The audits took place within one of the 
physician’s offices; sensitive information such as a patient’s name, birth date, home 
address, or phone number was not generated in the results or findings of this capstone.  
This researcher did not discuss any sensitive patient information with any employee or 
provider of the clinic who was not on a “need-to-know” basis and did not discuss any 
information with any individual outside of the clinic setting.  The researcher adhered to 
the strict policies of HIPAA and fully understood the ramifications.  
Summary 
 All four physicians involved in this study understood that the USPSTF’s (2015) 
recommendation of screening adults born between 1945 and 1965 for HCV was useful 
and important.  By educating the providers, this researcher successfully increased the 
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providers’ awareness of HCV and therefore the importance of screening this birth cohort.  
Eagle Ridge Medical and the Fort Lupton clinics did not currently have a screening alert 
(reminder) established within the EHR. The four physicians admitted they had not 
screened this birth cohort before based on the USPSTF’s recommendation and without 
alarming medical symptoms that might have prompted them to screen these adults in the 
past.  The recommendation to screen this birth cohort was without regard to medical 
symptoms and therefore asymptomatic adults were recommended to be screened.  
Ultimately, this researcher anticipated that screening rates would increase once the 
screening alert (reminder) was implemented within the EHR and as a result of mailing 
informative letters to patients born between 1945 and 1965.  The letter was generic based 
on the physicians’ requests, included the USPSTF’s recommendation for screening of a 
blood-borne disease, and informed the patient to ask about the screening at his/her next 
appointment.  Costs affiliated with this project were projected to be less than $2,000 and 
were mainly associated with envelopes and postage to mail the informative letters and 
normal results.  The clinic utilized the EHR so further costs from support and changes 
within this system for the development of the screening reminder (alert) and flow sheet 
were not incurred.  Overall, this researcher anticipated an increase in screening rates 
amongst this birth cohort after implementation of the screening alert (reminder) in the 
EHR was executed.  It was also anticipated that the screening rates would increase once 
patients received the informative letters from the clinic and came in to have their blood 












RESULTS AND OUTCOMES 
 
 
 The objective of this capstone project was to increase screening rates of patients 
born in the “Baby Boomer” generation (born between the years of 1945 and 1965) at the 
Eagle Ridge Medical (in Brighton) and the Fort Lupton clinic.  This chapter presents the 
results based on the planned evaluation.  Two different methods were utilized for 
establishing baseline screening rates; they included a chart audit of 5% of the whole 
population of adults born between 1945 and 1965 at both clinic sites and a chart audit on 
all patients born in this timeframe who were seen at both of these clinic sites in the six 
weeks prior to informative letters being mailed and the alert reminder for HCV screening 
in the EHR.  These two different methods were utilized to gather screening rates on 
active patients (patients seen in the last six weeks) and a random chart audit of all 
registered patients to reach less actively seen patients. 
Results Linked to Problem Statement  
and Evaluation Plan 
 A chart audit was performed on 5% (n = 95) of the 1,906 patients of Eagle Ridge 
Medical and the affiliated Fort Lupton clinic as two of the physicians at Eagle Ridge 
Medical floated to this sister clinic a couple of days per week.  The list of patients was 
compiled from MDS and initially, 1,933 patients were listed.  Subsequently, 27 patients 
were excluded for various reasons: 18 were duplicate patient entries into the EHR, four 
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were deceased, three were discharged from the practice, and two were test patients.  Data 
for the chart audit were collected by auditing every 10th patient in alphabetical order.  Of 
the 95 patients audited for the purpose of this chart audit, three patients had been 
screened already, which resulted in 3.2% of this population.  Three different physicians 
ordered the anti-HCV antibody tests on their patients; one of the physicians worked at 
Eagle Ridge Medical while the other two physicians worked at an affiliated internal 
medicine office in Brighton and another family practice clinic located at the Reunion site 
in Commerce City.  All three of these patients were screened in the last two years.  One 
of the physicians ordered the test because of an increased liver function test (LFT)--ALT 
of 77 (normal range: 21-72) and aspartate aminotransferase (AST) of 66 (normal range: 
17-59).  Another patient was tested due to a slight increase in LFTs (ALT of 59 and AST 
of 45) per the physician.  The third patient was tested due to unknown reasons.  The 
physician did not justify or state the reason in the affiliated progress note.  All three of the 
patients tested from this chart audit were negative for the Hepatitis C virus.  
Four hundred sixty-seven patients were seen in the six weeks before project 
implementation and born within the time frame of 1945 to 1965.  One patient was 
excluded from the review due to death within the time period, which left 466 patients for 
the purpose of this chart audit to establish baseline screening rates. Three of the 466 
patients seen in the past six weeks were screened for HCV, which meant 0.6% of this 
population was screened for the Hepatitis C virus prior to implementation of the 
screening alert in the EHR and mailing of informative letters.  One patient requested the 
HCV testing as well as screening for HIV and STDs.  The reasoning behind this request 
was not documented in the record.  The second patient requested testing for HCV 
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because, per the physician’s progress note, he admitted to having unprotected sexual 
encounters with multiple partners and was experiencing fatigue.  The third patient was 
tested for HCV due to a rash and his significant other requesting he be tested for STDs 
that included blood-borne diseases.  All three patients tested for HCV in the past six 
weeks had negative results and all three physicians who ordered the anti-HCV antibody 
tests worked at Eagle Ridge Medical.  
An alert reminder was created in the EHR for the providers to screen for HCV if a 
patient was born in the years 1945 to 1965.  Informative letters intended to notify the 
patient of the USPSTF’s (2015) recommendation to be screened for a blood-borne 
disease were also mailed to the Baby Boomer generation in case they did not achieve an 
appointment at the clinic over the next several weeks and therefore would not have been 
given the opportunity to be screened for HCV otherwise. 
The researcher met individually with all four physicians seven calendar days after 
initiation of this project (implementation of the alert within the EHR and mailing of 
informative letters).  The researcher met with the physicians to ensure they were 
acknowledging the alert in the EHR and subsequently screening the Baby Boomer 
population.  All four physicians (100%) stated they had been screening this population 
and the alert in the EHR was helpful as a reminder.  All of the physicians agreed and 
admitted that by the end of the appointment with the patient, sometimes they would 
forget to screen the patient as the alert popped up immediately when the patient’s chart 
was opened and disappeared after one acknowledged it.  Regardless, all four physicians 
felt the screening rate for each of them had definitely increased.  They denied having any 
questions or concerns at that time.  
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A chart audit was performed on 5% of the 1,906 patients (n = 95) of the Eagle 
Ridge Medical and Fort Lupton clinic at the end of the six-week mark.  Results of the 
chart audit were collected by auditing every 10th patient in alphabetical order following 
the first 95 patients who were previously audited.  Of the 95 patients audited, seven of 
them had been screened (7.3%), an increase of 4.1% in comparison to the similar chart 
audit completed (which was 3.2%) prior to initiation of the interventions.  Of the seven 
patients screened, three were screened in the past six weeks due to the recommendation 
as they were born between the years 1945 and 1965 and the remaining four were 
screened for various reasons.  One patient was screened because this individual worked 
with HIV-positive children and requested HIV testing as well as HCV testing.  Another 
patient, a widow, was screened per request for STD testing including blood-borne 
diseases in case this person pursued another relationship.  Per the physician’s progress 
note, this patient denied symptoms or concerns regarding exposure.  The other patient 
was tested due to a slightly increased AST (49) with a normal range of 14-36.  The ALT 
was within normal limits (39) and this patient, per this physician’s progress note, denied 
use of alcohol.  All seven patients screened from this chart audit tested negative for the 
Hepatitis C virus.  All three physicians who ordered these tests worked at Eagle Ridge 
Medical in Brighton and these patients were all screened within the last three years. 
A chart audit was performed six weeks after implementation of the screening 
reminder alert in the EHR and mailing of informative letters.  The chart audit was 
performed on 421 patients seen in the previous six weeks.  Of the 421 patients seen, 57 
(13.5%) were screened for HCV due to the recommendation.  There was a 12.9% 
increase from the initial baseline screening rate of 0.6%.  Of the 57 patients screened 
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after implementation of the alert in the EHR and mailing of informative letters, 56 
patients tested negative for the Hepatitis C virus and one patient tested positive (reactive 
to hepatitis C) with the subsequent genotype 1a and an RNA of 14,200,000 IU/mL, which 
meant the patient had active, chronic Hepatitis C.  Per the physician, the testing was done 
due to the recommendation but the patient did admit to having chronic fatigue as well.  
The researcher of this project investigated the patient’s comprehensive metabolic panel 
and the patient had an ALT of 43, AST of 25, and a total bilirubin level of 0.4.  All of 
these test results were within the normal range.  Table 1 provides the screening rates prior 
to and after project implementation 
 
Table 1 





Total Clinic Population Screening Rate 
 
  
Patients born between 1945-1965 
 
1906 1906 
Population screened using 5%  
(n = 95) systematic sampling  
 
3 (3.2%) 7 (7.3%) 














Extent to Which Objectives Were Achieved 
 It is clear to see the objectives of this capstone project were achieved.  The 
physicians agreed they were all screening the patient population based on the USPSTF 
(2015) guidelines and screening rates increased.  The researcher of this capstone project 
expected rates to increase more than 13.5%; however, perhaps with a longer timeframe, 
rates would have increased even more.  The alert reminder in the EHR was effective in 
increasing the screening rate, although it had limited reach in the clinic’s population.  
This researcher assumes the screening will continue to increase, even though the alert in 
the EHR for HCV screening has been deleted, because of the informative letters mailed 
to this patient population as this was the best method of reaching the majority of the 
patients.  The researcher anticipates some of the patients who received the letters might 
not have come to the clinic yet or were waiting until a future appointment (e.g., a 
physical) until they asked what the screening entailed.  
Key Facilitators and Barriers 
 Key facilitators primarily included the physicians of Eagle Ridge Medical and the 
Fort Lupton clinic who agreed to screen this patient population based on USPSTF’s 
(2015) recommendations. All four physicians (100%) stated compliance with screening 
the patients born between 1945 and 1965 and found it was helpful to have a reminder 
(screening alert in the EHR) to prompt them.  The researcher identified an increase in 
screening rates both due to the physicians screening the patients during their 
appointments and due to the informative letters mailed to the patients.  The researcher 
combined results of patients being screened in the clinic and letters mailed in collecting 
this data; therefore, she was unable to determine which patients were screened for HCV 
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due to the providers doing so from the alert reminder in the EHR or from the informative 
letters the patients received in the mail.  
 The front desk staff and the Medical Assistants were also key facilitators as they 
received multiple phone calls with regard to the letters and answered them appropriately 
by telling the patients they did not need to accomplish an appointment with their provider 
if they simply wanted to come to the clinic for the blood draw.  The Medical Assistants 
informed this researcher that they drew multiple patients’ blood for HCV.  They mailed 
normal results to the patients who had normal (negative) findings but for the patient who 
was found to be positive for HCV, they called the patient to inform this person to make 
an appointment with their physician.  The Medical Assistants did not relay the positive 
result over the phone as this was the physician’s responsibility.  The Medical Assistants 
also offered the Fact Sheet from the CDC (2016; see Appendix G) that was made 
available in the lab of the clinic for patients.  
 The researcher was a key facilitator as she made multiple contacts with MDS in 
ensuring the EHR trigger alert (reminder) was implemented appropriately and was 
activated for all patients born between 1945 and 1965 at the Eagle Ridge Medical and 
Fort Lupton locations. She spent 45+ hours hand-addressing all 1,906 envelopes, printing 
the letters, stuffing the envelopes with the letters to patients born between these years, 
and ensuring the letters were mailed to patients.  The researcher was readily available for 
any questions or concerns the office staff had.  No significant barriers were identified 
with this capstone project although it would have been more cost and time efficient if the 
EHR could have generated letters and mailing labels for not only this informative letter 




 Overall, the researcher deemed this capstone project as beneficial and successful 
in increasing the screening rates for HCV of the Baby Boomer population.  The 
physicians and office manager all agreed this project was useful and worthwhile and the 
physicians made great efforts in screening the patients during appointments.  They 
relayed the importance of the EHR screening reminder alert and said it did indeed prompt 
them to screen patients.  The Medical Assistants were an essential part of this project as 
they received “walk-in” patients who received letters in the mail and the front desk staff 
answered multiple phone calls with regard to the letters and gave patients appropriate 
information.  
 There were no unintended consequences of this capstone project but the 
researcher, as she anticipated, identified a significantly higher increase of screening rates 
for the Hepatitis C virus amongst the Baby Boomer generation in the six-week period. 
The researcher assumed the screening rate would increase more after implementation of 
the screening alert (reminder) in the EHR and mailing of informative letters and 
anticipates the screening rate will continue to rise over time.  The researcher noted a 
4.1% increase of screening rates when she did the chart audit on 5% of the 1,906 patients 
(n = 95) at the Eagle Ridge Medical and Fort Lupton sites and a 12.9% increase when she 
did the audits of patients seen in the six weeks prior to and six weeks after project 
implementation (alert reminder in the EHR and mailing of informative letters).  While the 
physicians stated they were screening this patient population, they all admitted they 
sometimes forgot to screen a patient for HCV as the alert reminder in the EHR only 
appeared upon opening the patient’s chart.  It is understandable how a provider might 
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forget to screen the patient or order the test at the end of the appointment.  The physicians 
informed this researcher that many patients who were offered the screening had declined 
it for various reasons (such as they were already screened once before or they did not feel 
they were considered high-risk).  However, this author was not able to capture an exact 
number of patients who refused screening because the physicians did not consistently 
annotate this in their progress notes.  Per the physicians’ progress notes, the researcher of 
this capstone noted eight documented patients who declined the screening.  The reasons 
varied including three patients felt they were not high-risk, four patients stated they had 
been screened before, and one patient stated they did not have time for a blood draw that 









RECOMMENDATIONS AND IMPLICATIONS FOR PRACTICE 
 
 
 The objectives of this Capstone project were to increase screening rates of 
patients born between 1945 and 1965 at the Eagle Ridge Medical and Fort Lupton clinic 
sites.  These objectives were carried out by implementing an alert reminder in the EHR to 
act as a cue for providers to screen this high-risk population and also by mailing 
informative letters to the entire patient population at both of these sites (N = 1,906) to 
ensure all patients born in this timeframe were being reached.  In this chapter, the 
researcher provides recommendations for the clinics where this project was implemented 
and how the project would likely prove to be beneficial in further increasing screening 
rates if continued.  The researcher also includes recommendations regarding 
implementation of this project in other family practice settings as it is applicable and 
beneficial.  
Recommendations 
 It is this researcher’s recommendation that the project conducted on screening the 
Baby Boomer generation (adults born between the years 1945 and 1965) for the Hepatitis 
C virus at Eagle Ridge Medical and the Fort Lupton clinics be continued.  The alert 
reminder in the EHR was turned off after the six-week mark; however, it would likely be 
beneficial to keep this alert in place to prompt and remind the providers to screen this 
patient population for HCV.  This would be especially useful for new patients of the 
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clinic and for patients the letters did not reach.  Out of the 1,906 letters mailed, 90 of 
them were returned (4.7%) primarily due to the patient no longer living at a specified 
address.  Other recommendations this researcher makes include: 
 The informative letter be included with each “new patient” packet made 
available at the clinic for patients born between the years 1945 and 1965. 
This way the entire Baby Boomer population at these family practice clinics 
will be reached including new patients as letters were already sent to 
established patients born in this timeframe. 
 The alert reminder be generated for the Medical Assistant so the alert can be 
addressed and consent obtained for ordering the test to save the provider 
time.  The provider would then see the test had been ordered and not 
duplicate it. 
 Implement a change within the EHR so the alert reminder is generated under 
the “Plan” page.  This is where the providers order tests and prescribe 
medications and would be a beneficial area within the EHR to have this alert 
because the provider could mention it to the patient and order it if the patient 
was willing to undergo the testing. 
It is understandable that these types of newer national recommendations take time 
to integrate into practice.  It is the researcher’s hope that if this screening 
recommendation for HCV is continued in the EHR, the providers and Medical Assistants 
will become accustomed to screening the Baby Boomer population without having the 
alert reminder prompt them.  Implementing the alert in the “Plan” of the EHR is a type of 
automatic screening similar to colonoscopies or mammograms; these screenings seem 
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engrained in most providers and are generally offered without needing the EHR alert 
reminder.  There are no ongoing evaluations needed for phases outside the scope of this 
DNP project at this time. 
 Within the framework of the organization’s strategic plan, the providers and the 
office manager would need to be in agreement that this recommendation of screening 
adults born between 1945 and 1965 is useful and beneficial, especially from a long-term 
aspect.  The office manager and providers are aware treatment is available for individuals 
who have active, chronic HCV and understand referrals to gastroenterologists or 
hepatologists are deemed warranted and necessary for a patient to begin a treatment 
regimen.  If screening the Baby Boomer population for HCV was to continue, the office 
manager would need to disseminate the message to the Medical Assistants and the front 
desk staff to ensure everyone is aware of the screening and to require the informative 
letters be a part of a “new patient” packet.  The Medical Assistants would likely be 
responsible for ensuring the lab area was always stocked with the Fact Sheet from the 
CDC (2016) and the lead Medical Assistant would perhaps be responsible for ensuring 
this Fact Sheet was updated by looking at the CDC website at least quarterly.   
  This capstone project would definitely be applicable in other family practice 
settings.  It is a national recommendation from the USPSTF (2015) to screen all Baby 
Boomer generation patients at least once in their lifetime.  As seen from the researcher’s 
chart audits at Eagle Ridge Medical and Fort Lupton clinics, a small amount of patients 
had been screened prior to implementation of this project.  The researcher anticipates 
most clinics in the nation do not have a standardized approach for screening this 
population for HCV, especially if the patient is asymptomatic.  It is important to 
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understand that this population is deemed high-risk and therefore screening is warranted 
and recommended.  Education would likely need to be delivered regarding not only the 
importance of the screening but also with regard to treatment availability and the high 
success cure rate (90-100%).  
Contribution to Personal Goals 
 This researcher felt this capstone project contributed to her personal goals as an 
advanced practice nurse and as a leader.  She felt she was organized and focused; she 
effectively disseminated the message regarding Hepatitis C screening in the Baby 
Boomer population by creating the alert within the EHR system and mailing letters to the 
entire patient population at the Eagle Ridge Medical and Fort Lupton clinic sites.  Often 
times, education is spread by “word of mouth” and it was this researcher’s thought that 
patients who heard about HCV screening (either through an appointment with their 
provider or receiving an informative letter in the mail) would then discuss it with other 
people including family members or friends and, subsequently, the recommendation of 
this screening would be dispersed.  After conducting this type of capstone project, this 
researcher is excited about the potential of implementing similar types of evidence-based 
changes amongst practices in the future.  Eagle Ridge Medical is an innovative clinic that 
certainly seems to embody the importance of maintaining the most current 
recommendations and evidence in order to provide the best possible care to the patients 
they serve.  It is this researcher’s hope that most family practice clinics are similar to 






 Screening this high-risk population, adults born between the years 1945 and 1965, 
for the Hepatitis C virus is a Grade B recommendation from the USPSTF (2015) and one 
worth doing.  The researcher of this capstone project deemed it successful as screening 
rates increased after implementation of the alert reminder in the EHR, prompting the 
physicians to screen this high-risk population, and mailing of informative letters to 
capture the entire patient population at the Eagle Ridge Medical and Fort Lupton clinic 
sites.  It is likely other family practice clinics would benefit from screening the Baby 
Boomer generation as well as it would allow the opportunity for treatment if patients 
tested positive for HCV.  The researcher of this capstone project felt this project was 
successful even though a drastic increase of screening rates was not seen.  An increase 
was seen overall and was particularly notable with the short, six-week timeframe. 
Perhaps a longer timeframe would have proven to be more successful in increasing 
screening rates.  With that being said, however, the researcher thoroughly enjoyed 
working on this project and felt it enhanced her personal leadership goals by effectively 
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Recommendation for Each Recommendation 
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To whom it may concern, 
 
You are receiving this letter because you are born between the years 1945-1965. The 
United States Preventive Services Task Force (USPSTF), a group of national experts in 
evidence-based medicine that focus on keeping people well, recommends screening 
adults born between these years for a blood-borne disease.   
 
Please ask about the details of this screening at your next appointment with your provider 
or contact the clinic at 303-659-1152 if you wish to learn more. The testing includes 
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